- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04635501
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
Prospective, Multicenter, Single Arm, Pre-CE Marked Study of the AbsorbaSeal (ABS 5.6.7) Vascular Closure Device
Study Overview
Detailed Description
With the increased number of percutaneous interventions being performed in outpatient settings, there is a growing need to obtain safer, faster, and more secure hemostasis following these procedures. Due to its automatic deployment feature and simplicity in operation. AbsorbaSeal (ABS 5.6.7) will lead to more widespread use and improve patient outcomes. The active closure system used in the ABS 5.6.7 ensures a secure closure. The composition of the seal used is completely bio-absorbable and does not require the use of adjunct materials (i.e. collagen, sutures, staples, etc.) needed in many of the devices currently available.
Extensive laboratory testing, acute animal labs and deployment in chronic animal studies were performed with ABS 6. After a few device modification to create the improved ABS 5.6.7, only minimal confirmatory testing was performed with the current, modified ABS 5.6.7. The extensive test results on the previous device iterations are used to complete the confirmatory testing of the ABS 5.6.7 design.
The First in Man (FIM) trial (CP001) supports the initial safety and effectiveness of ABS 5.6.7 in humans (n=20) and was completed prior to application for a pivotal Investigational Device Exemption (IDE) Study in the United States and a CE Mark Study approval (CP004CE) in the European Union.
The primary objective of this study is to assess the safety and effectiveness of the ABS 5.6.7. Enrollment into this study will include anatomically eligible patients requiring diagnostic and interventional procedures. Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures, and health-related quality of life.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium, 9300
- O.L.V. Hospital
-
Dendermonde, Belgium, 9200
- A.Z. Sint-Blasius
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient, male or female, minimum age of 18
- Patient provides written Informed Consent
- Patient is scheduled for a peripheral diagnostic or interventional procedure
- Patient is able to undergo emergent vascular surgery if a complication related to the VCD necessitates such surgery
- Patient has a 6French arterial puncture located in the common femoral artery (CFA)
- Target vessel has a lumen diameter > 5 mm
- Patient is willing and able to comply with all Study visits and procedures and complete follow-up visit
- Catheterization procedure is planned and elective
Pre-Procedure Exclusion Criteria:
- Prior target artery closure with any closure device or closure with manual compression ≤ 30 days prior to the peripheral catheterization procedure
- History of significant bleeding or with any known or documented bleeding disorders, such as thrombocytopenia (with < 100,000 platelet count), von Willebrand disease, anemia (Hgb < 10 g/Dl, Hct < 30%), thrombasthenia, decreased fibrinogen (< 200 mg/Dl), and Factor V deficiency
- Acute ST-elevation myocardial infarction ≤ 48 hours prior to the peripheral catheterization procedure
- Ineligible for introducer sheath removal
- Thrombolytic therapy (e.g. streptokinase, urokinase, t-PA) ≤ 24 hours prior to the peripheral catheterization procedure
- Evidence of a preexisting hematoma, arteriovenous fistula, or pseudo-aneurysm at the access site prior to start of femoral artery closure procedure
- Prior femoral vascular surgery or vascular graft in region of access site or contralateral common femoral artery
- Targeted femoral artery is tortuous or requires a sheath length > 10 cm
- Pregnant or lactating
- Mean body mass index (BMI) > 35 kg/m²
- Existing nerve damage in ipsilateral limb
- Fibrotic, heavily calcified femoral artery within 10mm of the entry point
- Non-palpable pulses in affected access limb
Intra-Procedure Exclusion Criteria:
- Difficult insertion of procedural sheath, needle stick problems at the onset of the peripheral procedure or difficult insertion of ABS 5.6.7
- Procedural sheath placement either through superficial femoral artery or into the profunda femoris artery or placement at or distal to bifurcation of the superficial femoral artery and the profunda femoris artery
- Common femoral artery (CFA) puncture site located above the lowest sweep of the inferior epigastric artery; referred to as a "high stick"
- Common femoral artery (CFA) access puncture site located on the front wall that continues through the back wall of the targeted vessel; referred to as a "back wall stick"
- Common femoral artery (CFA) access puncture site with multiple punctures of the CFA in an attempt to gain access to the targeted vessel known as "multiple sticks"
- Common femoral artery (CFA) access puncture located in the side wall region of the targeted access vessel; referred to as a "side wall stick"
- Interventional procedures with multiple exchanges during the procedure that cause elongation and trauma to the vessel compromising the tight seal between the vessel and the sheath
- Hematoma developing during the course of the percutaneous procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ABS 5.6.7
Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
|
Patients whose access site will be closed with the ABS 5.6.7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of major complications
Time Frame: Post-procedure follow up 30 ± 7 days
|
Composite of (1) closure-related bleeding requiring transfusion, (2) closure related vascular injury requiring repair surgery, (3) new ipsilateral lower extremity ischemia causing a threat to viability of limb requiring surgical or endovascular intervention, (4) closure-related infection requiring intravenous antibiotics and/or extended hospitalization, (5) new onset closure-related neuropathy in the ipsilateral lower extremity requiring surgical repair, and (6) permanent closure-related nerve damage.
|
Post-procedure follow up 30 ± 7 days
|
Time to hemostasis (TTH) after index procedure (min)
Time Frame: Intraoperative
|
TTH is defined as elapsed time between ABS 5.6.7 removal and first observed hemostasis
|
Intraoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of minor complications
Time Frame: Post-procedure follow up 30 ± 7 days
|
Composite of (1) closure-related bleeding requiring > 30 min. of continual manual compression to achieve initial arterial hemostasis, (2) late closure-related arterial bleeding (following hospital discharge), (3) closure-related hematoma > 6 cm, (4) Ipsilateral lower extremity arterial emboli, (5) ipsilateral deep vein thrombosis, (6) closure-related vessel laceration, (7) access site wound dehiscence, (8) localized access site infection treated with intramuscular or oral antibiotics, (9) closure related arteriovenous fistula not requiring treatment, (10) closure related pseudo-aneurysm requiring thrombin injection or fibrin adhesive injection, (11) closure related pseudo-aneurysm not requiring treatment, and (12) new onset of transient access site closure related neuropathy in the ipsilateral lower extremity that is transient (> 24 hrs.
and < 30 days) and does not require surgical repair
|
Post-procedure follow up 30 ± 7 days
|
Device success
Time Frame: Within 5 minutes following ABS 5.6.7 deployment
|
Device Success defined as the ability to deploy the implant and achieve arterial hemostasis with ABS 5.6.7 alone or with post hemostasis adjunctive manual compression for 5 minutes or less.
|
Within 5 minutes following ABS 5.6.7 deployment
|
Procedure success
Time Frame: Post-procedure follow up 30 ± 7 days
|
Procedure Success defined as attainment of final arterial hemostasis using any method.
|
Post-procedure follow up 30 ± 7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Koen Deloose, MD, AZ Sint Blasius
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP004CE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on ABS 5.6.7
-
Nimbic Systems, LLCUnknownProsthesis-Related InfectionsUnited States
-
Nimbic Systems, LLCBaylor College of Medicine; National Institute of General Medical Sciences...CompletedSurgical Site InfectionUnited States
-
University of NottinghamNottingham University Hospitals NHS TrustCompletedSecondary Progressive Multiple SclerosisUnited Kingdom
-
Assiut UniversityUnknownAntiphospholipid Antibodies & Osteopontin as Risk Factors for Cerebrovascular Stroke in Young AdultsStroke in Young AdultsEgypt
-
Acibadem UniversityUnknownHematoma | Radial Artery Injury | BleedTurkey
-
Hospices Civils de LyonActive, not recruiting
-
Intermountain Health Care, Inc.CompletedTraumatic Brain InjuryUnited States
-
University of OxfordActive, not recruiting
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Hospital Universitari de BellvitgeUnknownInflammatory Bowel Diseases | Clostridium DifficileSpain